Alnylam presents positive results from helios-a phase 3 study of investigational vutrisiran

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced full positive results from the helios-a phase 3 study of vutrisiran, an investigational rnai therapeutic in development for the treatment of transthyretin-mediated (attr) amyloidosis, which met its primary and both secondary endpoints at nine months in patients with hereditary attr (hattr) amyloidosis with polyneuropathy. the results were presented today in an
ALNY Ratings Summary
ALNY Quant Ranking